N/A N=7 Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma
Neovascular Glaucoma
Primary: Incidence of Adverse Events — 3; 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=54 Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients
Glaucoma, Neovascular
Primary: Change in Intraocular Pressure (IOP) From Baseline to Pre-dose at Week 1 — -8.5; -4.9 mmHg — p=0.0644
Phase 3 N=295 Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration
Neovascular Age-Related Macular Degeneration
Primary: Number of Patients With no Disease Activity at Week 16 in the Study Eye — 89 Participants
Phase 2 N=8 Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging
Proliferative Diabetic Retinopathy
Primary: The Mean Percentage Change of the Area of the Patient's Neovascularization as Measured in Pixels by Optomap FA (Fluorescein Angiography) — -83.8; 52.6; 11.3; 55.4…
Phase 3 N=16 Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied
Glaucoma, Neovascular
Primary: Change in Intraocular Pressure (IOP) From Baseline to Week 1 — -8.3 mmHg — p=0.0004
Phase 2 N=70 Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy
Glaucoma, Open-Angle
Primary: Percentage of Patients With a Visual Field Improvement in the Study Eye — 12.0; 9.5; 4.2 Percentage of Patients
Phase 2 N=20 Treatment of Corneal Neovascularization With Topical Pazopanib
Corneal Neovascularization
Primary: Heart Rate — 68.7 Beats per Minutes
Phase 4 N=59 Use of Bevacizumab in Trabeculectomy Surgery
Glaucoma · Optic Neuropathy · Fibrosis
Primary: Intraocular Pressure — 13.9; 13.2 mm Hg — p=<0.05
Phase 2 N=14 Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.
Wet Macular Degeneration · Age-related Macular Degeneration · Diabetic Macular Edema
Primary: Mean Central Subfield Thickness (CST) — 422.9; 419.7; 364.5; 346.7 microns
Phase 4 N=35 Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study
Glaucoma; Drugs · Normal Tension Glaucoma · Primary Open-angle Glaucoma
Primary: Changes in Vessel Density in Treatment Groups Assessed by OCT Angiography — -0.51; 2.59; -0.96; 0.96 percent change
Phase 3 N=52 Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration
Neovascular Age-related Macular Degeneration · Wet Macular Degeneration
Primary: Change in Mean Central Subfield Thickness (CST) — -36.6; 1.7 microns — p=0.04
Phase 2 N=365 Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
Neovascular Age-Related Macular Degeneration
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 12 — 5.2; 5.6; 5.4…
Phase 4 N=31 Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO
Retinal Vein Occlusion · Diabetic Macular Edema · Branch Retinal Vein Occlusion
Primary: Change in Panretinal Leakage Index at Month 12 From Baseline — -3.14 percentage of region of interest in UWFA
Phase 3 N=210 A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration
Neovascular Age Related Macular Degeneration
Primary: Percentage Change in Choroidal Neovascularization (CNV) Lesion Area Measured by Optical Coherence Tomography-Angiograph (OCT-A) From Baseline to Week 12 — -79.29 %…
N/A N=160 Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration
Neovascular Age-related Macular Degeneration
Primary: Vision — 0.16 logMAR
N/A N=7 Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG)
Glaucoma
Primary: Presence of Retinal Vascular Dysregulation (RVD) — 7; 4 Participants
Phase 4 N=49 Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab
Exudative Age-related Macular Degeneration
Primary: Caliber of Choroidal New Vessel (CNV) — 43.53 micrometer
Phase 1 N=1 Intravitreal Mesenchymal Stem Cell Transplantation in Advanced Glaucoma.
Retinal Degeneration · Primary Open-angle Glaucoma
Primary: Type and Severity of Adverse Effects (AE) and Adverse Reactions (AR) — 1 Participants
N/A N=15 Glaucoma Surgery Using the ViaLase Laser System
Glaucoma · Glaucoma, Open-Angle
Primary: Mean IOP — 12.7 mmHg
Phase 4 N=154 Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)
Age - Related Macular Degeneration (AMD)
Primary: Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score From Baseline to Week 100 - Last Observation Carried Forward (LOCF) — 58.7; 4.5 letters…
Phase 2 N=40 Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions
Macular Edema · Retinal Vein Occlusion
Primary: Best Corrected Visual Acuity Change From Baseline at All Visits — 10.5; 15.1 ETDRS letters
N/A N=16 Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma
Primary Open Angle Glaucoma
Primary: Blood Oxygenation — 60; 60; 60 percentage of oxygenation
Phase 4 N=26 The IAI-OCTA Study; a Study of OCT-Angiography Analysis Efficacy
Wet Macular Degeneration
Primary: Area of Lesion Measured by Optical Coherence Tomography Angiography (OCTA) Scan. — 1.07 mm^2
Phase 2 N=510 Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
Macular Degeneration
Primary: Change From Baseline in Best-corrected Visual Acuity (BCVA) as Measured by the Number of Letters Read on the Early Treatment of Diabetic Retinopathy Study (ETDRS)…
Phase 1 N=24 Topical Avastin for Treatment of Corneal Neovascularization
Corneal Neovascularization
Primary: The Size and Extent of Corneal Neovascularization Will be Measured by Computerized Image Analysis of Corneal Photographs Taken Throughout the Study. — 27.9 percent…
Phase 4 N=271 Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye
Macular Degeneration
Primary: Change in BCVA as Measured by the ETDRS Letter Score — -2.1; -0.4 Letters correctly read — p=0.0162
Phase 2 N=22 Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT)
Age Related Macular Degeneration · Choroidal Neovascularization · Macular Edema
Primary: Visual Acuity: Percentage of Patients Losing 3 or More Lines(15 Letters) of Visual Acuity From Baseline. — 80; 90 percent of participants
Phase 3 N=205 Anti-VEGF vs. Prompt Vitrectomy for VH From PDR
Proliferative Diabetic Retinopathy · Vitreous Hemorrhage
Primary: E-ETDRS Visual Acuity Letter Score (Area Under the Curve From Baseline) — 59.3; 63.0 units on a scale
N/A N=5 Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema
Uveitis · Cystoid Macular Edema
Primary: Improvement in VA ETDRS >/= 15 Letters — 1 participants
Phase 2 N=119 Ahmed Glaucoma Valve Surgery With Mitomycin-C
Glaucoma · Primary Open Angle Glaucoma · Secondary Glaucoma
Primary: Intraocular Pressure After Surgery — 13.1; 16.2 mmHg